Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | NMT2 | O60551 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509407 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL6838077 | 0.88 | ALOX5 (0.51) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL11700179 | 0.88 | KDM4E (0.49) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL11746504 | 0.82 | MCL1 (0.67) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL8082611 | 0.82 | KDM4E (0.51) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL3607399 | 0.79 | KDM4E (0.76) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL8074490 | 0.78 | RAB9A (0.48) | KDM4EHSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL7553333 | 0.77 | AKR1B1 (0.53) | KDM4EHSD17B10ALDH1A1HPGDMEN1 | |
| SCHEMBL8082560 | 0.76 | RAB9A (0.46) | KDM4EHSD17B10NPC1RAB9AMEN1 | |
| SCHEMBL6837905 | 0.76 | MAOB (0.53) | KDM4EHSD17B10ALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | KDM4E 2531/4885HSD17B10 2675/4885NPC1 3745/4885 |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | KDM4E 2674/4885HSD17B10 2519/4885NPC1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.